StockUS listing USNNVCAMEXHealthcareCapital Destroyer

NanoViricides Inc(NNVC) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk63Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · AMEX
Market cap 31.41M
Reward Ratingⓘ34 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ63 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NNVC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is NanoViricides Inc?

, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.

AI Brief Pro

The brief on NanoViricides Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is NanoViricides Inc?

, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 31.41M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.829
Insider Activity
12M windowNo data
No insider activity data available for this ticker.